Petr Doležel

1.3k total citations
61 papers, 1.1k citations indexed

About

Petr Doležel is a scholar working on Molecular Biology, Oncology and Pharmaceutical Science. According to data from OpenAlex, Petr Doležel has authored 61 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 14 papers in Oncology and 11 papers in Pharmaceutical Science. Recurrent topics in Petr Doležel's work include Drug Transport and Resistance Mechanisms (13 papers), Advanced Drug Delivery Systems (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Petr Doležel is often cited by papers focused on Drug Transport and Resistance Mechanisms (13 papers), Advanced Drug Delivery Systems (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Petr Doležel collaborates with scholars based in Czechia, Austria and Japan. Petr Doležel's co-authors include Petr Mlejnek, Petr Kosztyu, David Vetchý, Jiřı́ Vrba, Jitka Ulrichová, Jaroslav Vičar, Jan Gajdziok, Stanislav Procházka, Vladimír Divoký and Jan Muselík and has published in prestigious journals such as SHILAP Revista de lepidopterología, Cancer Cell and International Journal of Molecular Sciences.

In The Last Decade

Petr Doležel

61 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Petr Doležel Czechia 20 450 190 178 108 102 61 1.1k
Ranjeet Prasad Dash United States 21 441 1.0× 146 0.8× 138 0.8× 18 0.2× 90 0.9× 52 1.2k
Feifei Yang China 23 748 1.7× 234 1.2× 89 0.5× 48 0.4× 96 0.9× 83 1.5k
Maria Cláudia Santos‐Silva Brazil 22 439 1.0× 99 0.5× 103 0.6× 90 0.8× 52 0.5× 85 1.3k
D. Bissett United Kingdom 24 455 1.0× 504 2.7× 151 0.8× 32 0.3× 45 0.4× 54 2.1k
Chandraiah Godugu India 22 426 0.9× 144 0.8× 140 0.8× 30 0.3× 92 0.9× 87 1.5k
Atif Zafar India 16 418 0.9× 166 0.9× 24 0.1× 86 0.8× 101 1.0× 28 1.2k
Chuanlong Guo China 25 627 1.4× 200 1.1× 133 0.7× 14 0.1× 88 0.9× 90 1.7k
Priyanka Arya India 12 260 0.6× 68 0.4× 124 0.7× 35 0.3× 45 0.4× 46 751
Karmen Stankov Serbia 20 480 1.1× 303 1.6× 118 0.7× 30 0.3× 70 0.7× 64 1.5k

Countries citing papers authored by Petr Doležel

Since Specialization
Citations

This map shows the geographic impact of Petr Doležel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Petr Doležel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Petr Doležel more than expected).

Fields of papers citing papers by Petr Doležel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Petr Doležel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Petr Doležel. The network helps show where Petr Doležel may publish in the future.

Co-authorship network of co-authors of Petr Doležel

This figure shows the co-authorship network connecting the top 25 collaborators of Petr Doležel. A scholar is included among the top collaborators of Petr Doležel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Petr Doležel. Petr Doležel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mlejnek, Petr, et al.. (2025). Some new aspects of erastin-induced ferroptosis in cancer cells. Chemico-Biological Interactions. 419. 111632–111632. 1 indexed citations
2.
Mlejnek, Petr, et al.. (2017). Reversal of ABCB1 mediated efflux by imatinib and nilotinib in cells expressing various transporter levels. Chemico-Biological Interactions. 273. 171–179. 26 indexed citations
3.
Mlejnek, Petr & Petr Doležel. (2014). N-acetylcysteine prevents the geldanamycin cytotoxicity by forming geldanamycin–N-acetylcysteine adduct. Chemico-Biological Interactions. 220. 248–254. 11 indexed citations
4.
Vysloužil, Jakub, et al.. (2014). Long-term controlled release of PLGA microparticles containing antidepressant mirtazapine. Pharmaceutical Development and Technology. 21(2). 214–221. 10 indexed citations
5.
Vysloužil, Jakub, Petr Doležel, Eliška Mašková, et al.. (2014). Influence of different formulations and process parameters during the preparation of drug-loaded PLGA microspheres evaluated by multivariate data analysis. Acta Pharmaceutica. 64(4). 403–417. 49 indexed citations
6.
Kosztyu, Petr, et al.. (2014). Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. Chemico-Biological Interactions. 219. 203–210. 51 indexed citations
7.
Vetchý, David, et al.. (2013). Determination of dependencies among in vitro and in vivo properties of prepared mucoadhesive buccal films using multivariate data analysis. European Journal of Pharmaceutics and Biopharmaceutics. 86(3). 498–506. 28 indexed citations
8.
Dvořáčková, Kateřina, et al.. (2013). The Effect of Acid pH Modifiers on the Release Characteristics of Weakly Basic Drug from Hydrophlilic–Lipophilic Matrices. AAPS PharmSciTech. 14(4). 1341–1348. 29 indexed citations
9.
Slany, Robert K., Jiřina Bártková, Viktor Stránecký, et al.. (2012). DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL-Induced Leukemogenesis In Vivo. Cancer Cell. 21(4). 517–531. 53 indexed citations
10.
Kosztyu, Petr, Petr Doležel, & Petr Mlejnek. (2012). Can P-glycoprotein mediate resistance to nilotinib in human leukaemia cells?. Pharmacological Research. 67(1). 79–83. 23 indexed citations
11.
Mlejnek, Petr, Petr Doležel, & Ivo Frydrych. (2012). Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations. Journal of Physiology and Biochemistry. 69(3). 405–417. 13 indexed citations
12.
Mlejnek, Petr, Petr Doležel, & Petr Kosztyu. (2011). P‐glycoprotein mediates resistance to A3 adenosine receptor agonist 2‐chloro‐N6‐(3‐iodobenzyl)‐adenosine‐5′‐n‐methyluronamide in human leukemia cells. Journal of Cellular Physiology. 227(2). 676–685. 18 indexed citations
13.
Doležel, Petr, et al.. (2011). Assay for determination of daunorubicin in cancer cells with multidrug resistance phenotype. Journal of Chromatography B. 879(21). 1875–1880. 17 indexed citations
14.
Doležel, Petr, Petra Koudelková, & Petr Mlejnek. (2010). Halogenation of N6-benzyladenosine decreases its cytotoxicity in human leukemia cells. Toxicology in Vitro. 24(8). 2079–2083. 7 indexed citations
15.
Mlejnek, Petr, Ondřej Novák, & Petr Doležel. (2010). A non-radioactive assay for precise determination of intracellular levels of imatinib and its main metabolite in Bcr-Abl positive cells. Talanta. 83(5). 1466–1471. 19 indexed citations
16.
Koledová, Zuzana, et al.. (2009). Cdk2 Inhibition Prolongs G1 Phase Progression in Mouse Embryonic Stem Cells. Stem Cells and Development. 19(2). 181–194. 51 indexed citations
17.
Frydrych, Ivo, Petr Mlejnek, & Petr Doležel. (2009). Cyclosporin A sensitises Bcr-Abl positive cells to imatinib mesylate independently of P-glycoprotein expression. Toxicology in Vitro. 23(8). 1482–1490. 9 indexed citations
18.
Vrba, Jiřı́, Petr Doležel, Jaroslav Vičar, & Jitka Ulrichová. (2009). Cytotoxic activity of sanguinarine and dihydrosanguinarine in human promyelocytic leukemia HL-60 cells. Toxicology in Vitro. 23(4). 580–588. 59 indexed citations
19.
Frydrych, Ivo, et al.. (2008). The broad-spectrum caspase inhibitor Boc-Asp-CMK induces cell death in human leukaemia cells. Toxicology in Vitro. 22(5). 1356–1360. 4 indexed citations
20.
Žı́dek, Lukáš, Petr Doležel, Josef Chmelı́k, A. G. Baker, & Miloš V. Novotný. (1997). Modification of Horse Heart Cytochrome c with trans-2-Hexenal. Chemical Research in Toxicology. 10(6). 702–710. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ranjeet Prasad Dash Breakdown of academic impact, for papers by Feifei Yang Breakdown of academic impact, for papers by Maria Cláudia Santos‐Silva Breakdown of academic impact, for papers by D. Bissett Breakdown of academic impact, for papers by Chandraiah Godugu Breakdown of academic impact, for papers by Atif Zafar Breakdown of academic impact, for papers by Chuanlong Guo Breakdown of academic impact, for papers by Priyanka Arya Breakdown of academic impact, for papers by Karmen Stankov
Rankless by CCL
2026